4.49
-0.26(-5.47%)
Currency In USD
| Previous Close | 4.75 |
| Open | 4.64 |
| Day High | 4.83 |
| Day Low | 4.38 |
| 52-Week High | 12.9 |
| 52-Week Low | 1.6 |
| Volume | 1.38M |
| Average Volume | 860,590 |
| Market Cap | 333.41M |
| PE | -3.28 |
| EPS | -1.37 |
| Moving Average 50 Days | 3.64 |
| Moving Average 200 Days | 3.17 |
| Change | -0.26 |
If you invested $1000 in Perspective Therapeutics, Inc. (CATX) 10 years ago, it would be worth $309.66 as of October 19, 2025 at a share price of $4.49. Whereas If you bought $1000 worth of Perspective Therapeutics, Inc. (CATX) shares 5 years ago, it would be worth $790.49 as of October 19, 2025 at a share price of $4.49.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
GlobeNewswire Inc.
Oct 02, 2025 11:00 AM GMT
SEATTLE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced
Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
GlobeNewswire Inc.
Sep 15, 2025 11:00 AM GMT
First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab[212Pb]VMT01 3.0 mCi single agent dose Cohort re-opened SEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AM
Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer
GlobeNewswire Inc.
Sep 04, 2025 11:00 AM GMT
Distinguished career as a Wall Street analyst and significant CFO experience, bringing keen insights and understanding of finance and the life sciences investment landscapeSEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.